Immunome Inc. - Common Stock, par value $0.0001 per share (IMNM)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
IMNM on Nasdaq
Shares outstanding
110,897,279
Price per share
$21.48
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
91,384,562
Total reported value
$1,070,118,014
% of total 13F portfolios
0%
Share change
+11,806,828
Value change
+$140,282,314
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
153
Price from insider filings
$21.15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Immunome Inc. - Common Stock, par value $0.0001 per share (IMNM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +113% $152,894,064 +$80,670,694 13,056,709 +112% FMR LLC 30 Sep 2025
T. Rowe Price Investment Management, Inc. 12% $124,649,133 10,644,674 T. Rowe Price Investment Management, Inc. 31 Oct 2025
Redmile Group, LLC 6.2% $45,677,313 5,361,187 Redmile Group, LLC 31 Mar 2025
Point72 Asset Management, L.P. 5.9% $41,638,177 4,887,110 Point72 Asset Management, L.P. 31 Jan 2025
Immunome Aggregator, LP 6% $40,628,327 4,768,583 Immunome Aggregator, LP 31 Jan 2025
Enavate Sciences GP, LLC 4.3% $73,483,864 4,768,583 Enavate Sciences GP, LLC 18 Dec 2025
VANGUARD GROUP INC 5.2% +7.8% $42,082,054 +$14,150,080 4,524,952 +51% The Vanguard Group 30 Jun 2025
EcoR1 Capital, LLC 4.7% $34,756,616 4,079,415 EcoR1 Capital, LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 2.2% -55% $16,313,738 -$13,130,862 1,914,758 -45% JANUS HENDERSON GROUP PLC 31 Mar 2025
As of 30 Sep 2025, Immunome Inc. - Common Stock, par value $0.0001 per share (IMNM) has 153 institutional shareholders filing 13F forms. They hold 91,384,562 shares. of 110,897,279 outstanding shares (82%) .

Top 25 institutional shareholders own 72% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 12% 13,056,709 +112% 0.01% $152,894,062
T. Rowe Price Investment Management, Inc. 7.6% 8,418,163 +1.7% 0.06% $98,577,000
BlackRock, Inc. 5.3% 5,822,736 +0.9% 0% $68,184,238
Redmile Group, LLC 4.5% 5,023,385 +3.1% 5.7% $58,823,838
VANGUARD GROUP INC 4.4% 4,893,626 +8.1% 0% $57,304,359
Point72 Asset Management, L.P. 4.4% 4,824,504 +3% 0.12% $56,494,942
ENAVATE SCIENCES GP, LLC 4.3% 4,768,583 0% 17% $55,840,107
EcoR1 Capital, LLC 3.7% 4,079,415 0% 2.3% $47,769,950
PRICE T ROWE ASSOCIATES INC /MD/ 3.4% 3,742,770 +26% 0% $43,829,000
Opaleye Management Inc. 2.9% 3,185,000 -9.8% 5.3% $37,296,350
PRIMECAP MANAGEMENT CO/CA/ 2.7% 3,018,009 -0.07% 0.03% $35,340,897
STATE STREET CORP 2.5% 2,803,973 +11% 0% $32,834,524
Jefferies Financial Group Inc. 1.9% 2,100,000 +0.69% 0.23% $24,591,000
GEODE CAPITAL MANAGEMENT, LLC 1.7% 1,894,575 +1.8% 0% $22,188,380
MORGAN STANLEY 1.7% 1,833,818 +354% 0% $21,474,020
READYSTATE ASSET MANAGEMENT LP 1.2% 1,318,290 -2.6% 0.75% $15,437,176
Woodline Partners LP 1.1% 1,274,729 -23% 0.07% $14,927,077
PRINCIPAL FINANCIAL GROUP INC 1% 1,104,938 +222% 0.01% $12,938,824
Polar Capital Holdings Plc 0.95% 1,058,776 +5.9% 0.06% $12,398,267
Caption Management, LLC 0.94% 1,040,700 0.71% $12,186,597
TORONTO DOMINION BANK 0.93% 1,036,056 -50% 0.02% $12,132,216
Candriam S.C.A. 0.78% 859,527 +170% 0.05% $10,065,061
CITADEL ADVISORS LLC 0.76% 841,138 0.01% $9,849,726
JANUS HENDERSON GROUP PLC 0.69% 763,175 -27% 0% $8,936,780
NORTHERN TRUST CORP 0.64% 706,515 +2.2% 0% $8,273,291

Institutional Holders of Immunome Inc. - Common Stock, par value $0.0001 per share (IMNM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 209,329 $4,496,018 +$2,893,131 2,148% 5
2025 Q3 91,384,562 $1,070,118,014 +$140,282,314 1,171% 153
2025 Q2 79,431,966 $738,692,421 +$30,839,753 930% 142
2025 Q1 76,944,016 $518,447,649 +$156,654,047 673% 141
2024 Q4 53,313,664 $566,321,086 -$37,080,544 1,062% 119
2024 Q3 51,629,246 $754,701,793 +$58,776,153 1,462% 114
2024 Q2 47,779,242 $578,110,445 +$106,966,991 1,210% 112
2024 Q1 36,616,859 $903,617,775 +$377,900,927 2,468% 102
2023 Q4 21,490,560 $229,948,765 +$205,035,908 1,070% 57
2023 Q3 2,729,076 $22,706,803 +$3,521,335 835% 36
2023 Q2 1,949,082 $15,421,801 +$698,301 791% 35
2023 Q1 1,860,095 $9,343,739 -$1,198,225 499% 30
2022 Q4 2,100,648 $4,845,087 -$694,148 221% 28
2022 Q3 2,300,040 $10,208,297 -$14,594 443.46% 23
2022 Q2 2,313,613 $7,426,000 -$1,197,731 320.93% 24
2022 Q1 2,694,238 $15,433,000 -$858,955 567.76% 26
2021 Q4 2,790,928 $36,364,000 +$4,810,967 1,296.12% 28
2021 Q3 2,391,433 $58,321,000 +$6,054,335 2,434.58% 31
2021 Q2 2,376,109 $41,107,000 +$6,432,363 1,730.02% 25
2021 Q1 1,909,240 $64,673,000 +$1,324,022 3,386.38% 30
2020 Q4 2,013,500 $19,489,000 +$19,489,000 967.95% 24